In mice bearing B16-OVA-CD19 melanoma tumours, CD19-targeting CAR-T cells lacking all three NR4As display significantly enhanced control of tumour growth compared to WT CAR-T cells, and were characterised by distinctly less exhausted, more effector-like phenotype capable of increased cytokine production (73). This evidence concerns the gene CD19 and melanoma.